Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry. Register now to see our 7 Best Stocks for the Next 30 Days report - free today!
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Which healthcare stock can dividend investors safely buy? Let's consider two excellent options: AbbVie (NYSE: ABBV) and Amgen ...
GlobalData on MSN14d
Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlightAs the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.
These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...
Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.
Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...
“Amgen Inc. (NASDAQ:AMGN) is a large cap global biotech company with a diverse portfolio of marketed and pipeline products. Amgen’s discovery pipeline had led the company to broaden its focus ...
Discover how Amgen is achieving a fully automated enterprise through strategic partnerships with Cognizant and UiPath to enhance efficiency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback